4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with dolutegravir in 1 studies
| Studies (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Trials (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Recent Studies (post-2010) (4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol) | Studies (dolutegravir) | Trials (dolutegravir) | Recent Studies (post-2010) (dolutegravir) |
|---|---|---|---|---|---|
| 70 | 12 | 9 | 1,128 | 179 | 1,105 |
| Protein | Taxonomy | 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol (IC50) | dolutegravir (IC50) |
|---|---|---|---|
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Solute carrier family 22 member 2 | Homo sapiens (human) | 1.9 | |
| Integrase | Human immunodeficiency virus 1 | 0.0414 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amata, E; Artacho-Cordón, A; Barbaraci, C; Cobos, EJ; Dichiara, M; Gómez-Guzmán, M; González-Cano, R; Marrazzo, A; Pasquinucci, L; Rodríguez-Gómez, I; Santos-Caballero, M; Turnaturi, R | 1 |
1 other study(ies) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and dolutegravir
| Article | Year |
|---|---|
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation.
Topics: Animals; Guinea Pigs; Hydrogen; Hydrogen Sulfide; Ligands; Male; Morpholines; Pain; Piperazines; Rats, Sprague-Dawley; Receptors, sigma; Sigma-1 Receptor | 2022 |